Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study

Hereditary Cancer in Clinical Practice

Kevin S Kimbro³  Shirish S Barve⁶  Guy N Brock¹  Seian Morrison⁴  Marshall Tulloch-Reid⁴  Norma McFarlane-Anderson⁴  Maria Jackson⁴  Camille Ragin⁵  James E Rudd³  Sydney Beache²  Nayla C Kidd²  Erica N Rogers²  Dominique Z Jones²  LaCreis R Kidd² 

[1] Department of Bioinformatics & Biostatistics, University of Louisville, School of Public Health & Information Sciences, 485 East Gray Street, Louisville, KY, 40202, USA;Department of Pharmacology & Toxicology, University of Louisville Clinical Translational Research Building, 505 South Hancock Street Room 306, Louisville, KY, 40202, USA;Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 531 Nelson Street, Durham, NC, 27707, USA;Department of Community Health and Psychiatry, University of West Indies, Ring Road, Mona, Jamaica;Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA;School of Medicine, University of Louisville, 323 East Chestnut Street, Louisville, KY, 40292, USA

关键词: Men of African descent;    Single nucleotide polymorphisms;    Chemokine receptor 5;    Chemokine ligand 5;    Chemokine receptors;    Chemokines;    Prostate cancer;   

Others  :  806252
DOI  :  10.1186/1897-4287-10-16

 received in 2012-10-09, accepted in 2012-10-29,  发布年份 2012

【 摘 要 】

Background

Chemokine and chemokine receptors play an essential role in tumorigenesis. Although chemokine-associated single nucleotide polymorphisms (SNPs) are associated with various cancers, their impact on prostate cancer (PCA) among men of African descent is unknown. Consequently, this study evaluated 43 chemokine-associated SNPs in relation to PCA risk. We hypothesized inheritance of variant chemokine-associated alleles may lead to alterations in PCA susceptibility, presumably due to variations in antitumor immune responses.

Methods

Sequence variants were evaluated in germ-line DNA samples from 814 African-American and Jamaican men (279 PCA cases and 535 controls) using Illumina’s Goldengate genotyping system.

Results

Inheritance of CCL5 rs2107538 (AA, GA+AA) and rs3817655 (AA, AG, AG+AA) genotypes were linked with a 34-48% reduction in PCA risk. Additionally, the recessive and dominant models for CCR5 rs1799988 and CCR7 rs3136685 were associated with a 1.52-1.73 fold increase in PCA risk. Upon stratification, only CCL5 rs3817655 and CCR7 rs3136685 remained significant for the Jamaican and U.S. subgroups, respectively.

Conclusions

In summary, CCL5 (rs2107538, rs3817655) and CCR5 (rs1799988) sequence variants significantly modified PCA susceptibility among men of African descent, even after adjusting for age and multiple comparisons. Our findings are only suggestive and require further evaluation and validation in relation to prostate cancer risk and ultimately disease progression, biochemical/disease recurrence and mortality in larger high-risk subgroups. Such efforts will help to identify genetic markers capable of explaining disproportionately high prostate cancer incidence, mortality, and morbidity rates among men of African descent.

【 授权许可】

   
2012 Kidd et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]American Cancer S: Cancer Facts and Figures 2012. Atlanta, Georgia: American Cancer Society; 2012.
• [2]American Cancer S: Cancer Facts & Figures for African Americans 2011–2012. Atlanta: American Cancer Society; 2011.
• [3]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Canc 2010, 127(12):2893-2917.
• [4]Luster AD: Chemokines–chemotactic cytokines that mediate inflammation. N Eng J Med 1998, 338(7):436-445.
• [5]Rollins BJ: Chemokines. Blood 1997, 90(3):909-928.
• [6]Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP: CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005, 16(6):593-609.
• [7]Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al.: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270(45):27348-27357.
• [8]Chang CC, Chen SC, Hsieh YH, Chen YC, Chen TY, Chu YH, Ma HJ, Chou MC, Tsai HT, Yang SF: Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med 2009, 47(4):412-418.
• [9]Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, Tanaka Y, Dahiya R: CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Canc Res 2007, 13(17):5056-5062.
• [10]Liou JM, Lin JT, Huang SP, Wu CY, Wang HP, Lee YC, Chiu HM, Shun CT, Lin MT, Wu MS: RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J Gastroenterol 2008, 43(2):115-123.
• [11]Vindrieux D, Escobar P, Lazennec G: Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009, 16(3):663-673.
• [12]Soria G, Ben-Baruch A: The CCL5/CCR5 axis in cancer. New York: Human Press; 2009.
• [13]Vaday GG, Peehl DM, Kadam PA, Lawrence DM: Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006, 66(2):124-134.
• [14]Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420(6917):860-867.
• [15]Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, Jimenez-Baranda S, Garzon A, Lacalle RA, Harshman K, et al.: CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003, 198(9):1381-1389.
• [16]Zhernakova A, Alizadeh BZ, Eerligh P, Hanifi-Moghaddam P, Schloot NC, Diosdado B, Wijmenga C, Roep BO, Koeleman BP: Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes. Genes Immun 2006, 7(7):544-549.
• [17]An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, Vlahov D, Buchbinder S, Farrar WL, Modi W, et al.: Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002, 99(15):10002-10007.
• [18]Saenz-Lopez P, Carretero R, Cozar JM, Romero JM, Canton J, Vilchez JR, Tallada M, Garrido F, Ruiz-Cabello F: Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 2008, 8:382. BioMed Central Full Text
• [19]Purdue MP, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M, Hosgood HD 3rd, Zahm SH, Chanock SJ, Rothman N, et al.: Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol 2011, 29(1):42-46.
• [20]Bracci PM, Skibola CF, Conde L, Halperin E, Lightfoot T, Smith A, Paynter RA, Skibola DR, Agana L, Roman E, et al.: Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma 2010, 51(3):497-506.
• [21]Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S, Reina O, Ardanaz MT, Jares P, Garcia-Orad A, et al.: Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 2008, 68(24):10178-10186.
• [22]Weng CJ, Chien MH, Lin CW, Chung TT, Zavras AI, Tsai CM, Chen MK, Yang SF: Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol 2010, 46(10):767-772.
• [23]Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA: Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Canc Epidemiol Biomarkers Prev 2006, 15(4):726-731.
• [24]Kidd LC, Vancleave TT, Doll MA, Srivastava DS, Thacker B, Komolafe O, Pihur V, Brock GN, Hein DW: No association between variant N-acetyltransferase genes, cigarette smoking and Prostate Cancer susceptibility among men of African descent. Biomark Cancer 2011, 2011(3):1-13.
• [25]Jackson MD, Walker SP, Simpson-Smith CM, Lindsay CM, Smith G, McFarlane-Anderson N, Bennett FI, Coard KC, Aiken WD, Tulloch T, et al.: Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. Canc Causes Contr 2012, 23(1):23-33.
• [26]Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, et al.: Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753.
• [27]McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008, 9(5):356-369.
• [28]Steemers FJ, Gunderson KL: Illumina, Inc. Pharmacogenomics 2005, 6(7):777-782.
• [29]Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, Buyyounouski M, Raysor S, Hooker S, Torres JB, Ramike T, et al.: Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer PrevRes(Phila Pa) 2009, 2(3):244-250.
• [30]Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF: A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. AmJHumGenet 2006, 79(4):640-649.
• [31]Menashe I, Rosenberg PS, Chen BE: PGA: power calculator for case–control genetic association analyses. BMC Genet 2008, 9:36.
• [32]Konig JE, Senge T, Allhoff EP, Konig W: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004, 58(2):121-129.
• [33]Petersen DC, Severi G, Hoang HN, Padilla EJ, Southey MC, English DR, Hopper JL, Giles GG, Hayes VM: No association between common chemokine and chemokine receptor gene variants and prostate cancer risk. Canc Epidemiol Biomarkers Prev 2008, 17(12):3615-3617.
• [34]Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M, Proudfoot AE: A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors. J Leukoc Biol 2001, 69(6):977-985.
• [35]Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, et al.: Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009, 5(12):e1000791.